Cheplapharm Arzneimittel Gmbh Patent-Cliff Exposure & CMS Drug Spending Portfolio

Cheplapharm Arzneimittel Gmbh (US): 7 reconciled FDA prescription therapies (0.6% 2025 to 2030 cliff risk), $96.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies7
2025 to 2030 Patent-Cliff Revenue Exposure0.6%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$96.2M
2024 Medicare Part D Spend$58.7M
2024 Medicaid Spend$37.5M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel